The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children
Abstract
Although 1% atropine effectively slows myopia progression, it is associated with adverse effects, including photophobia, blurred near vision, and poor compliance. We investigated whether lower doses of atropine would control myopia progression. One hundred and eighty-six children, from 6 to 13 years of age, were treated each night with different concentrations of atropine eye drops or a control treatment for up to 2 years. The mean myopic progression in each of the groups was 0.04 +/-0.63 diopter per year (D/Y) in the 0.5% atropine group, 0.45+/-0.55 D/Y in the 0.25% atropine group, and 0.47+/-0.91 D/Y in the 0.1% atropine group. All atropine groups showed significantly less myopic progression than the control group (1.06+/-0.61 D/Y) (p<0.01). Our study also showed that 61% of students in the 0.5% atropine group, 49% in the 0.25% atropine group and 42% in the 0.1% atropine group had no myopic progression. However, 4% of children in the 0.5% atropine group, 17% in the 0.25% atropine group, and 33% in the 0.1% atropine group still had fast myopic progression (>-1.0 D/Y). In contrast, only 8% of the control group showed no myopic progression and 44% had fast myopic progression. These results suggest that all three concentrations of atropine had significant effects on controlling myopia; however, treatment with 0.5% atropine was the most effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Local Retinal Regions Control Local Eye Growth and Myopia
Wallman, J., Gottlieb, M. D., Rajaram, V., & Fugate-Wentzek, L. A. (1987) · Science · doi:10.1126/science.3603011 · Cited by 515
Developing eyes that lack accommodation grow to compensate for imposed defocus
Schaeffel, F., Troilo, D., Wallman, J., & Howland, H. C. (1990) · Visual Neuroscience · doi:10.1017/s0952523800002327 · Cited by 212
The effect of atropine on myopia.
Rh, B. (1971) · PubMed · Cited by 74
Peters, J. R., Evans, P. J., Page, M. D., Hall, R., GIBBS, J. T., Diéguez, C., & Scanlon, M. F. (1986) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1986.tb01684.x · Cited by 56
INHIBITION OF PHYSIOLOGICAL GROWTH HORMONE SECRETION BY ATROPINE
Taylor, B. J., SMITH, P. J., & Brook, C. G. D. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb00149.x · Cited by 37
Cited by
Nickla, D. L., & Wallman, J. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.12.002 · Cited by 1,945
Homeostasis of Eye Growth and the Question of Myopia
Wallman, J., & Winawer, J. (2004) · Neuron · doi:10.1016/j.neuron.2004.08.008 · Cited by 1,060
Chia, A., Chua, W.-H., Cheung, Y.-B., Wong, W.-L., Lingham, A., Fong, A., & Tan, D. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.07.031 · Cited by 852
Baird, P. N., Saw, S.-M., Lanca, C., Guggenheim, J. A., Smith III, E. L., Zhou, X., Matsui, K.-O., Wu, P.-C., Sankaridurg, P., Chia, A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00231-4 · Cited by 838
Retardation of Myopia in Orthokeratology (ROMIO) Study: A 2-Year Randomized Clinical Trial
Cho, P., & Cheung, S.-W. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10565 · Cited by 818
Metadata
- Authors
- SHIH, Y.-F., CHEN, C.-H., CHOU, A.-C., HO, T.-C., LIN, L. L.-K., & HUNG, P.-T.
- Venue
- Journal of Ocular Pharmacology and Therapeutics
- Publisher
- SAGE Publications
- Published
- 1999-02
- Volume
- 15
- Issue
- 1
- Pages
- 85-90
- ISSN
- 1080-7683 (ISSN-L)
- 1557-7732
- OpenAlex
- W2005571511
- Cited by
- 279
- References
- 5
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.